Cargando…
Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVI...
Autores principales: | Jaberi-Douraki, Majid, Meyer, Emma, Riviere, Jim, Gedara, Nuwan Indika Millagaha, Kawakami, Jessica, Wyckoff, Gerald J., Xu, Xuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233397/ https://www.ncbi.nlm.nih.gov/pubmed/34172790 http://dx.doi.org/10.1038/s41598-021-92734-7 |
Ejemplares similares
-
Data mining methodology for response to hypertension symptomology—application to COVID-19-related pharmacovigilance
por: Xu, Xuan, et al.
Publicado: (2021) -
Global Trends in Cancer Nanotechnology: A Qualitative Scientific Mapping Using Content-Based and Bibliometric Features for Machine Learning Text Classification
por: Millagaha Gedara, Nuwan Indika, et al.
Publicado: (2021) -
An Automated Customizable Live Web Crawler for Curation of Comparative Pharmacokinetic Data: An Intelligent Compilation of Research-Based Comprehensive Article Repository
por: Ampadi Ramachandran, Remya, et al.
Publicado: (2023) -
Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality
por: Stafford, Emma G., et al.
Publicado: (2020) -
A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19()
por: Patel, Purva, et al.
Publicado: (2023)